Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work.
L, W., X, C., Z, H., J, R., W, L., & H, R. (2026). Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work.. Clinical physiology and functional imaging. https://doi.org/10.1111/cpf.70084
L W, X C, Z H, J R, W L, H R. Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work.. Clinical physiology and functional imaging. 2026; doi: 10.1111/cpf.70084
L W, X C, Z H, et al. Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work.[J]. Clinical physiology and functional imaging. 2026. DOI: 10.1111/cpf.70084.
@article{l2026,
author = {Wan L and Chen X and Huang Z and Ren J and Lu W and Ran H},
title = {Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work.},
journal = {Clinical physiology and functional imaging},
year = {2026},
doi = {10.1111/cpf.70084},
note = {PMID: 42504680},
}
TY - JOUR AU - Wan L AU - Chen X AU - Huang Z AU - Ren J AU - Lu W AU - Ran H TI - Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work. T2 - Clinical physiology and functional imaging PY - 2026 DO - 10.1111/cpf.70084 AN - PMID:42504680 ER -
OBJECTIVE: To evaluate the effect of 12-week Mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy (oHCM) using myocardial work analysis, and explore its role in myocardial energy metabolism. METHODS: Thirty-five oHCM patients and 35 matched healthy controls were enroled. Patients received Mavacamten for 12 weeks. At baseline and post-treatment, we measured LVOT gradient, LVEF, GLS, myocardial work parameters [GWI, GCW, GWW, GWE], mitral regurgitation severity, and SAM. RESULTS: Myocardial work parameters showed good reproducibility (ICCs > 0.75). After 12 weeks, resting and provoked LVOT gradients significantly decreased (both p < 0.001). Proportions of moderate/severe mitral regurgitation and SAM reduced. GWI, GCW, and GWW decreased (p < 0.001), while GWE increased (p < 0.001). NT-proBNP decreased and NYHA functional class improved (p < 0.001). LVEF, GLS, and left atrial diameter showed no significant changes. Compared with controls, baseline oHCM patients had lower GWI, GCW, GWE and higher GWW (all p < 0.001). After treatment, GWE remained lower than controls (p < 0.001), and GWW remained higher (p < 0.001). CONCLUSION: Twelve-week Mavacamten reduces LVOT obstruction in oHCM, accompanied by decreased GWI and increased GWE, while preserving systolic function and improving symptoms. Myocardial work parameters may serve as novel non-invasive references for treatment evaluation.